The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 52 of the 76 sources its claims cite were checked for support.
Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction
Open accessAbstract
The mechanism of action of eprenetapopt (APR-246, PRIMA-1 MET ) as an anticancer agent remains unresolved, although the clinical development of eprenetapopt focuses on its reported mechanism of action as a mutant-p53 reactivator. Using unbiased approaches, this study demonstrates that eprenetapopt depletes cellular antioxidant glutathione levels by increasing its turnover, triggering a nonapoptotic, iron-dependent form of cell death known as ferroptosis. Deficiency in genes responsible for supplying cancer cells with the substrates for de novo glutathione synthesis ( SLC7A11 , SHMT2 , and MTHFD1L ), as well as the enzymes required to synthesize glutathione ( GCLC and GCLM ), augments the activity of eprenetapopt. Eprenetapopt also inhibits iron-sulfur cluster biogenesis by limiting the cysteine desulfurase activity of NFS1, which potentiates ferroptosis and may restrict cellular proliferation. The combination of eprenetapopt with dietary serine and glycine restriction synergizes to inhibit esophageal xenograft tumor growth. These findings reframe the canonical view of eprenetapopt from a mutant-p53 reactivator to a ferroptosis inducer.
Overview
CoChat Summary
TL;DR
Eprenetapopt (APR-246) depletes glutathione by increasing its turnover, triggers iron-dependent nonapoptotic ferroptosis, and inhibits NFS1 cysteine desulfurase rather than acting primarily as a mutant-p53 reactivator. Combining eprenetapopt with dietary serine and glycine restriction synergizes to inhibit esophageal tumor growth in vivo.
Key findings
- Genome-wide CRISPR screens in OACM5.1 cells identified GSH synthesis genes as central modulators: SLC7A11 and GCLM dropped out in CRISPRko, GCLC was top enriched in CRISPRa, and mito-1C genes SHMT2 and MTHFD1L plus ESD also sensitized cells to eprenetapopt; TP53 and apoptotic machinery were not identified.
- Eprenetapopt decreased reduced GSH without increasing GSSG, and 13C2-cystine tracing showed increased incorporation into glutamylcysteine, GSH, GSSG, and cysteinylglycine, with MQ-GSH and MQ-cysteine adducts detected, indicating increased GSH turnover/degradation rather than blocked de novo synthesis.
- Eprenetapopt-induced cell death was rescued by ferrostatin-1 and ciclopirox olamine but not zVAD-FMK in H1299 and FLO-1 cells, and apoptosis-deficient MC38 cells lacking Bax/Bak/Bid/Casp3/Casp7 were still killed, supporting ferroptosis.
- MQ inhibited NFS1 cysteine desulfurase activity in cell-free and 293T assays and reduced aconitase activity; dietary serine/glycine restriction plus eprenetapopt (100 mg/kg daily) inhibited primary tumor growth, delayed metastasis, and prolonged survival in FLO-1 LM mice, and limited esophageal adenocarcinoma PDX growth.
Methods
- Multiomics approach: genome-wide CRISPRko (Brunello, 76,441 sgRNAs) and CRISPRa (Calabrese, 56,762 sgRNAs) screens in OACM5.1 esophageal cancer cells; untargeted LC-MS metabolomics and label-free quantitative proteomics after 50 μM eprenetapopt for 12 hours; DepMap/CTRPv2 correlation analyses.
- Cell death and mechanism assays: PI uptake/IncuCyte and alamarBlue viability; ferroptosis rescue with Fer-1, CPX, zVAD-FMK, or NAC; apoptosis-resistant MC38 cells; NFS1 cysteine desulfurase assays measuring H2S release or 35S-cysteine persulfide formation; aconitase activity assays.
- In vivo models: FLO-1 LM cell line xenografts and esophageal adenocarcinoma PDXs in NSG mice, randomized to normal or serine/glycine-free diet and eprenetapopt (100 mg/kg daily) or vehicle; tumor growth, bioluminescence metastasis, and survival analyzed with t tests, ANOVA, and log-rank tests.
Limitations
- The paper states that the precise mechanism by which eprenetapopt depletes GSH and inhibits NFS1 remains to be determined.
- Evident from the text: the CRISPRa screen was performed with n = 1, some assays had n = 1 or n = 2, and no power analyses were performed to determine sample size before experimentation.
- Evident from the text: eprenetapopt monotherapy failed to inhibit primary tumor growth or metastatic spread in the FLO-1 LM model, and efficacy in culture was limited by high cell confluency and low O2 levels; in vivo synergy was shown only in esophageal cancer models.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. Multiomics strategy to determine the MoA of eprenetapopt. (A) Schematic diagram showing a strategy to determine the MoA of eprenetapopt. (B) Heatmap of sensitivity to eprenetapopt analog (APR-017). Cancer lineages are ordered by sensitivity determined by delta median, area under the curve (AUC) of compound activity. Percentages denote the frequency of TP53 mutations in each lineage. CNS, central nervous system; PNS, peripheral nervous system. (C) Schematic showing the workflow for the CRISPRko and CRISPRa screens in OACM5.1 cells. (D) MAGeCK scores (negative indicating dropout and positive indicating “enrichment”) from CRISPR screens, plotted in order of magnitude. (E) Cellular metabolic activity measured by alamarBlue as a surrogate readout for cell viability following 72-hour exposure with eprenetapopt at indicated doses in cells transduced with individual sgRNA targeting identified hits. Heatmap represents the change in GI50 (dose where 50% growth inhibition is achieved) relative to control. (F) Fisher’s transformed z-scored Pearson correlation strength of gene dependency from the DepMap database with eprenetapopt analog (APR-017) sensitivity data from CTRPv2, plotted in order of magnitude. (G) Comparison of CRISPR screens and DepMap gene dependency data shows overlay of glutamate-cysteine ligase units (GCLC and GCLM). Plot is representing the rank of top hits (ordered by dropout in CRISPRko, by enrichment in CRISPRa, and by positive correlations in DepMap). Dashed lines indicate overlap of top 50 ranked genes. (H) Changes in polar metabolites determined by untargeted liquid chromatography–mass spectrometry (LC-MS) metabolomics and (I) proteins determined by label-free quantitative proteomics in OACM5.1 cells following treatment with 50 μM eprenetapopt for 12 hours compared to vehicle. Dotted lines indicate significance cutoffs {P < 0.05, |log2[fold change (FC)]| > 0.5}. Two-tailed unpaired t test (H and I). Error bars = SEM. (D) n = 2 for CRISPRko, n = 1 for CRISPRa, (E) n = 3 to 4, (H) n = 6, and (I) n = 4. See also fig. S1.](https://figures.cochat.ai/paper-figures/95778abe2c7e4affaca89228901ced2a/eprenetapopt-triggers-ferroptosis-inhibits-nfs1-cysteine-desulfurase-and-figure-1.jpg)

![Fig. 3. Eprenetapopt triggers ferroptosis. (A) Percentage (%) of dead cells [as determined by % PI+ cells] and percentage of cell confluency following treatment for 24 hours with 50 μM eprenetapopt with or without 50 μM zVAD-FMK (pan-caspase inhibitor), 12.5 μM Fer-1 (lipophilic antioxidant), 6.25 μM CPX (iron chelator), or 2.5 mM NAC (cysteine supplement) in H1299 (left) and FLO-1 cells (right). (B) Representative merged phase and red channel images of results from (A) acquired on IncuCyte. (C) Percentage of cell death determined by PI uptake following 24-hour treatment with 50 μM eprenetapopt in H1299 cells at indicated cell densities. (D) Immunoblot of Bax, Bak, Bid, Casp3, and Casp7 illustrating the efficiency of CRISPR editing in MC38 cells. (E) Left: Cell death in MC38 wild-type (WT) and apoptosis-deficient (Apop KO) cells following 24-hour treatment with 50 μM eprenetapopt or 12.5 μM STS. Right: Cellular metabolic activity measured by alamarBlue as a surrogate readout for cell viability following 72-hour exposure with eprenetapopt at indicated doses in wild-type and apoptosis-deficient MC38 cells. Two-way t test (A and E). *P < 0.05, **P < 0.01, and ****P < 0.0001. (A) n = 2 to 3, (D) n = 2, representative blots shown, and (E) n = 3. See also fig. S3 and movie S1.](https://figures.cochat.ai/paper-figures/d428f807eb644046bf7a14de31ff0dc3/eprenetapopt-triggers-ferroptosis-inhibits-nfs1-cysteine-desulfurase-and-figure-3.jpg)

Verification
Claims the paper makes
35 Valid · 1 Not valid · 14 Not checked · 87 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, in contradiction to previous investigations (9), we found that eprenetapopt treatment decreases the level of glutathionylation in cells (fig. S2K)”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Eprenetapopt and mito-1C metabolism
What the sources say
- Supportedcites [9] L. Haffo, J. Lu, V. J. N. Bykov, S. S. Martin, X. Ren, L. Coppo, K. G. Wiman, A. Holmgren, Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Sci. Rep. 8, 12671 (2018). 30140002 PMC6107631 source
The citation is attached to “previous investigations,” not to the citing authors’ finding of a decrease. In the Results section (“Total glutathionylation in Saos-2 and Saos-2-His-273 cells”), the source reports that glutathionylation increased with increasing APR-246 concentration, establishing the contrast the citing sentence describes. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This model is in keeping with our prior work, and confirmed by others (7, 8, 20), demonstrating that inhibiting cystine uptake with erastin or sulfasalazine synergizes with eprenetapopt both in vitro and in vivo.”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Eprenetapopt and mito-1C metabolism
What the sources say
- Partly supportedcites [7] S. Ceder, S. E. Eriksson, E. H. Cheteh, S. Dawar, M. C. Benitez, V. J. N. Bykov, K. M. Fujihara, M. Grandin, X. Li, S. Ramm, C. Behrenbruch, K. J. Simpson, F. Hollande, L. Abrahmsen, N. J. Clemons, K. G. Wiman, A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO Mol. Med. 13, e10852 (2021). 33314700 PMC7863383 sourceExperimental — accuracy not yet measured
The Discussion (page not available in our copy) says APR-246 synergizes with the cystine-uptake inhibitor sulfasalazine in vitro and reports an in vivo finding from Liu et al. (2017). The cell-culture results also describe sulfasalazine synergy. The passages do not support the erastin part of the claim. (LLM, conf=0.88)
- Partly supportedcites [8] D. S. Liu, C. P. Duong, S. Haupt, K. G. Montgomery, C. M. House, W. J. Azar, H. B. Pearson, O. M. Fisher, M. Read, G. R. Guerra, Y. Haupt, C. Cullinane, K. G. Wiman, L. Abrahmsen, W. A. Phillips, N. J. Clemons, Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 8, 14844 (2017). 28348409 PMC5379068 sourceExperimental — accuracy not yet measured
The Results section reports that both erastin and sulfasalazine (SAS) strongly synergized with APR-246 in cancer cells. In the in vivo xenograft experiments, it reports greater antitumour activity for SAS plus APR-246 than for either agent alone, but does not report an erastin combination in vivo. Thus the claim’s in vivo extension to both drugs is not supported by this paper. (LLM, conf=0.88)
- Partly supportedcites [20] R. Birsen, C. Larrue, J. Decroocq, N. Johnson, N. Guiraud, M. Gotanegre, L. Cantero-Aguilar, E. Grignano, T. Huynh, M. Fontenay, O. Kosmider, P. Mayeux, N. Chapuis, J. E. Sarry, J. Tamburini, D. Bouscary, APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica 107, 403– 416 (2022). 33406814 PMC8804578 sourceExperimental — accuracy not yet measured
The Results section on cystine uptake reports that erastin synergized with APR-246 in AML cell lines and primary samples in vitro. The in vivo Results section reports enhanced activity from combining APR-246 with genetic SLC7A11 knockdown, not erastin or sulfasalazine. Our copy does not report sulfasalazine synergy. (LLM, conf=0.89)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, two mito-1C metabolism genes, SHMT2 and MTHFD1L, and the S-formylglutathione hydrolase gene, ESD, involved in GSH-mediated formaldehyde detoxification (12) were identified in the CRISPRko screen.”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Multiomics strategy to determine the MoA of eprenetapopt
What the sources say
- Partly supportedcites [12] G. Burgos-Barragan, N. Wit, J. Meiser, F. A. Dingler, M. Pietzke, L. Mulderrig, L. B. Pontel, I. V. Rosado, T. F. Brewer, R. L. Cordell, P. S. Monks, C. J. Chang, A. Vazquez, K. J. Patel, Mammals divert endogenous genotoxic formaldehyde into one-carbon metabolism. Nature 548, 549– 554 (2017). 28813411 PMC5714256 sourceExperimental — accuracy not yet measured
The section ‘ADH5 fuels the growth of 1C-cycle-deficient cells’ describes S-formylglutathione hydrolase regenerating GSH as part of a formaldehyde-detoxification route. It does not identify that hydrolase as ESD. The citation is attached to the detoxification clause; this source does not report the claimed identification of SHMT2, MTHFD1L and ESD in a CRISPR knockout screen. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In our prior work, we showed that eprenetapopt induces lipid peroxidation following GSH depletion (8).”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Eprenetapopt triggers ferroptosis
What the sources say
- Supportedcites [8] D. S. Liu, C. P. Duong, S. Haupt, K. G. Montgomery, C. M. House, W. J. Azar, H. B. Pearson, O. M. Fisher, M. Read, G. R. Guerra, Y. Haupt, C. Cullinane, K. G. Wiman, L. Abrahmsen, W. A. Phillips, N. J. Clemons, Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 8, 14844 (2017). 28348409 PMC5379068 source
The Results section, “APR-246 triggers lipid peroxidation through depleting GSH” (page unavailable), reports that APR-246-induced GSH depletion leads to lipid peroxidation. The Discussion states the same mechanism directly; the paper uses the name APR-246 for eprenetapopt. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“eprenetapopt is the first compound to reach a phase 3 clinical trial where triggering ferroptosis is central to its anticancer efficacy.”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > DISCUSSION
What the sources say
- Could not verifycites [37] S. J. Dixon, D. N. Patel, M. Welsch, R. Skouta, E. D. Lee, M. Hayano, A. G. Thomas, C. E. Gleason, N. P. Tatonetti, B. S. Slusher, B. R. Stockwell, Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523 (2014). 24844246 PMC4054777 sourceExperimental — accuracy not yet measured
The Results sections on erastin analogs and sorafenib discuss ferroptosis in cancer cells and potential clinical use, but not eprenetapopt. Searches for eprenetapopt, APR-246, and phase 3 trials found no passage establishing that eprenetapopt reached such a trial or that ferroptosis is central to its anticancer efficacy. The cited paper's copy therefore does not address the attributed claim. (LLM, conf=0.76)
- Could not verifycites [21] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, R. Skouta, E. M. Zaitsev, C. E. Gleason, D. N. Patel, A. J. Bauer, A. M. Cantley, W. S. Yang, B. Morrison III, B. R. Stockwell, Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060– 1072 (2012). 22632970 PMC3367386 sourceExperimental — accuracy not yet measured
The Abstract and Discussion describe ferroptosis in cancer cells and discuss erastin, RSL3, and other experimental compounds. Searches for eprenetapopt and phase 3 clinical trials found no passage addressing that drug, its trial status, or its mechanism of anticancer efficacy; page numbers were not available in our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [38] J. Du, T. Wang, Y. Li, Y. Zhou, X. Wang, X. Yu, X. Ren, Y. An, Y. Wu, W. Sun, W. Fan, Q. Zhu, Y. Wang, X. Tong, DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic. Biol. Med. 131, 356– 369 (2019). 30557609 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 17 with their cited sources checked
Create a free account to see all 137 claims and every source verdict.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 33
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > INTRODUCTION
“Recent results from two phase 2 clinical trials in TP53-mutated MDS, combining eprenetapopt with standard-of-care azacitidine, reported rates of complete remission (CR) of ~50% (3, 4).”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > DISCUSSION
“Both phase 1 clinical trials demonstrated that patients who responded to eprenetapopt and azacitidine had significantly improved overall survival compared to nonresponders (3, 4)”
Citations
Cites
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691 · cited 2×
“Ferroptosis is a form of nonapoptotic cell death characterized by the induction and accumulation of toxic lipid membrane peroxidation catalyzed by iron ( 21 ).”
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“1 cells expressing Cas9-mCherry with the Brunello genome-wide CRISPR knockout (CRISPRko) library ( 10 ) and challenged these cells with a sublethal dose of epreneta-popt for 8 days (Fig.”
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 1×
“Further, while previous reports have indicated that p53 activation may be involved in triggering ferroptosis in cancer cells ( 36 ), p53-null cancer cells undergo ferroptosis in response to eprenetapopt treatment, demonstrating that p53 reactivation is dispensable for ferroptosis induced by…”
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897 · cited 1×
“…37 ), sulfasala-zine ( 21 ), artemisinin ( 38 ), and statins, as well as conventional chemotherapy, immune checkpoint inhibitors, and radiotherapy ( 39 ), have demonstrated capacity to induce or enhance sensitivity to ferroptosis, eprenetapopt is the first compound to reach a phase 3 clinical…”
Role of Mitochondria in Ferroptosis
Gao, M., Yi, J., Zhu, J., Minikes, A. M., Monian, P., Thompson, C. B., & Jiang, X. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.042 · Cited by 2,120 · cited 1×
“This is because ferroptosis induced by sustained cystine deprivation or erastin treatment perturbs cell proliferation beyond the induction lipid peroxidation ( 22 ).”
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088 · cited 1×
“While other clinical compounds including sorafenib ( 37 ), sulfasala-zine ( 21 ), artemisinin ( 38 ), and statins, as well as conventional chemotherapy, immune checkpoint inhibitors, and radiotherapy ( 39 ), have demonstrated capacity to induce or enhance sensitivity to ferroptosis, eprenetapopt is…”
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011 · cited 1×
“Hematological and neurological toxicities, as well as impaired renal function, have been reported in patients receiving eprene-tapopt ( 3 , 4 ), which is in line with reports demonstrating high sensitivity to ferroptosis among mesenchymal-derived tissues ( 41 ).”
Griffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683 · cited 1×
“Furthermore, eprenetapopt may be unique, triggering an increase in turnover of GSH rather than restraining de novo GSH synthesis, as imposed by erastin through its inhibition of cystine uptake or by l -buthionine sulfoximine through inhibition of glutamate-cysteine ligase ( 40 ).”
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Cysteine depletion induces pancreatic tumor ferroptosis in mice
Badgley, M. A., Kremer, D. M., Maurer, H. C., DelGiorno, K. E., Lee, H.-J., Purohit, V., Sagalovskiy, I. R., Ma, A., Kapilian, J., Firl, C. E. M., et al. (2020) · Science · doi:10.1126/science.aaw9872 · Cited by 1,294 · cited 1×
“Reflecting on recent reports suggesting that depletion of CoA contributes to the induction of ferroptosis by erastin ( 25 , 26 ), we first referred to our metabolomics dataset (Fig.”
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“…of pathways independent of p53, 401 – 404 such as downregulating glutathione concentrations in tumor cells, 405,406 regulating oxidation-reduction homeostasis 407 – 409 in tumor cells to trigger ferroptosis, 410 – 412 and inducing endoplasmic reticulum stress 413 or unfolded protein responses.”
BackgroundRecent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 275
“However, its mechanism may also target other synergistic pathways which can drive p53-independent cell death including modulation of cellular redox [156, 157] and increasing glutathione turnover, leading to ferroptosis [158].”
BackgroundFerroptosis: when metabolism meets cell death
Zheng, J., & Conrad, M. (2025) · Physiological Reviews · doi:10.1152/physrev.00031.2024 · Cited by 246
Exploiting ferroptosis vulnerabilities in cancer
Nakamura, T., & Conrad, M. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01425-8 · Cited by 159
“Eprenetapopt, which is in phase 3 clinical trials, can deplete GSH to induce ferroptosis 81,82 and inhibit cysteine desulfurase (NFS1) 83 .”
InfluentialRecommendations for robust and reproducible research on ferroptosis
Mishima, E., Nakamura, T., Doll, S., Proneth, B., Fedorova, M., Pratt, D. A., Friedmann Angeli, J. P., Dixon, S. J., Wahida, A., & Conrad, M. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00843-2 · Cited by 163
Metadata
- Authors
- Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., Hogg, S. J., Cabalag, C. S., Sutton, V. R., Watt, S., Fujihara, A. T., Trapani, J. A., Simpson, K. J., Stojanovski, D., Leimkühler, S., Haupt, S., Phillips, W. A., & Clemons, N. J.
- Affiliations
- The University of Melbourne (AU)
- University of Potsdam (DE)
- Moffitt Cancer Center (US)
- Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Memorial Sloan Kettering Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Fujihara, Kenji M.
- Clemons, Nicholas J.
- ORCID
- Fujihara, Kenji M.
- Jackson, Thomas D.
- Ogunkola, Moses O.
- Nijagal, Brunda
- Milne, Julia V.
- Sallman, David A.
- Ang, Ching-Seng
- Kearney, Conor J.
- Hogg, Simon J.
- Cabalag, Carlos S.
- Sutton, Vivien R.
- Fujihara, Asuka T.
- Trapani, Joseph A.
- Simpson, Kaylene J.
- Stojanovski, Diana
- Leimkühler, Silke
- Haupt, Sue
- Phillips, Wayne A.
- Clemons, Nicholas J.
- Venue
- Science Advances
- Published
- 2022-09-16
- Volume
- 8
- Issue
- 37
- Pages
- eabm9427-eabm9427
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC9473576
- OpenAlex
- W4295900094
- Cited by
- 102
- References
- 58
- Citations by year
- 2026: 30 · 2025: 30 · 2024: 24 · 2023: 15 · 2022: 3
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- publish.UP (University of Potsdam) (submittedVersion, cc-by)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Sulfur Compounds in Biology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- APR-246, ferroptosis, glutathione depletion, glutathione synthesis, iron-sulfur cluster assembly, NFS1, cysteine desulfurase, dietary restriction, esophageal cancer, SLC7A11, SHMT2, MTHFD1L, GCLC, GCLM, tumor growth inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. https://app.cochat.ai/papers/10.1126/sciadv.abm9427
- The paper
- Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., Hogg, S. J., Cabalag, C. S., Sutton, V. R., Watt, S., Fujihara, A. T., Trapani, J. A., Simpson, K. J., Stojanovski, D., Leimkühler, S., . . . Clemons, N. J. (2022). Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. Science Advances. https://doi.org/10.1126/sciadv.abm9427
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.